Pharmaceutically active compounds
US6756373B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 6, 2000 |
| Grant date | Jun 29, 2004 |
| Priority date | — |
| Expiry date | Oct 6, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P15/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
There is provided a compound of formula I: whereinX represents O or NR5 R4 represents H, halo, cyano, nitro, halo(loweralkyl), OR6, OC(O)R7, C(O)R8, C(O)OR9, C(O)NR10R11, NR12R13, NR16Y(O)R17, N[Y(O)R17]2, SOR18, SO2R19, C(O)AZ, lower alkyl, lower alkenyl, lower alkynyl, Het, alkylHet, aryl, alkylaryl (which latter seven groups are all optionally substituted with one or more substituents selected from halo, cyano, nitro, lower alkyl, halo(loweralkyl), OR6, OC(O)R7, C(O)R8, C(O)OR9, C(O)NR10R11, NR12R13 and SO2NR14R15)which are useful in the curative and prophylactic treatment of a medical condition for which inhibition of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase (e.g., cGMP PDE5) is desired.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.